Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Endotoxin Challenge in Asthma
NCT06270576Phase 1Not yet recruiting
- Sponsor
- National Jewish Health
- Start
- Apr 2024
- Primary completion
- Apr 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of escherichia coli endotoxin (2 arms), sponsored by National Jewish Health. Primary endpoint: Neutrophil heterogeneity using single cell RNA sequencing at 3 days. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
escherichia coli endotoxin
Beyond the preview
Go deeper on NCT06270576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06270576.